NASDAQ
No price data available for this timeframe.
Corvus Pharmaceuticals, Inc. (CRVS) has a free cash flow growth of -13.55% as of Friday, May 29, 2026. This represents a 95.26% decrease compared to its 12-month average of -6.94%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.